AA
NTLA icon

AlphaCentric Advisors’s Intellia Therapeutics NTLA Stock Holding History

AlphaCentric Advisors’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$197K Buy
11,672
+166
+1% +$2.32K 0.17% 161
2026
Q1 		$148K Buy
11,506
+626
+6% +$7.97K 0.15% 171
2025
Q4 		$97.8K Buy
+10,880
New +$150K 0.1% 223

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

AlphaCentric Advisors's NTLA Position: Q2 2026 in Review

AlphaCentric Advisors increased its Intellia Therapeutics (NTLA) stake by 1.4% in Q2 2026, buying an estimated $2.32K and bringing the position to 11,672 shares worth $197K. The position accounts for 0.17% of the portfolio, ranked #161.

AlphaCentric Advisors first reported a position in NTLA in Q4 2025 and has held it in 3 quarters since. 329 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

  • AlphaCentric Advisors held 11,672 shares of Intellia Therapeutics worth $197K as of Q2 2026.
  • AlphaCentric Advisors bought 166 Intellia Therapeutics shares in Q2 2026, an estimated $2.32K.
  • Intellia Therapeutics made up 0.17% of AlphaCentric Advisors's portfolio in Q2 2026, its #161 holding.
  • AlphaCentric Advisors first reported a position in Intellia Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 329 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on AlphaCentric Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.